ALBO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Mar 2023 @ 16:00):

Stats
Today's Volume	1.24M
Average Volume	566 901
Market Cap	915.89M
EPS	$0 ( 2023-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.63
ATR14	$0.932 (2.11%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Chiswell David	Sell	56 278	Common Stock
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	5 500	Stock Option (Right to Buy)

INSIDER POWER
-49.86
Last 100 transactions
Buy: 1 059 000 \| Sell: 2 762 067

Volume Correlation

Long: 0.36 (neutral)

Short: 0.10 (neutral)

Signal:(68.034) Neutral

Albireo Pharma Inc Correlation

10 Most Positive Correlations
WPRT	0.988
APTO	0.982
RESN	0.98
RXDX	0.977
RETA	0.972
MTEM	0.969
CSII	0.965
IMGN	0.963
VREX	0.963
ZGNX	0.962

10 Most Negative Correlations
AAON	-0.975
EYE	-0.975
THRX	-0.969
IEP	-0.962
APLS	-0.96
PEBK	-0.956
PINC	-0.956
VRAR	-0.952
BRQS	-0.95
NVCT	-0.948

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Albireo Pharma Inc Correlation - Currency/Commodity

-0.66
( moderate negative )

-0.69
( moderate negative )

0.36
( neutral )

0.08
( neutral )

0.17
( neutral )

0.81
( strong )

Albireo Pharma Inc Financials

Annual	2021
Revenue:	$40.58M
Gross Profit:	$39.22M (96.66 %)
EPS:	$-1.770

Q3	2022
Revenue:	$9.83M
Gross Profit:	$9.22M (93.78 %)
EPS:	$-1.950

Q2	2022
Revenue:	$8.21M
Gross Profit:	$7.43M (90.54 %)
EPS:	$-2.18

Q1	2022
Revenue:	$6.83M
Gross Profit:	$6.60M (96.57 %)
EPS:	$-2.34

Financial Reports:

No articles found.

Albireo Pharma Inc

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.